VANCOUVER, Aug. 4 /CNW/ - ALDA Pharmaceuticals Corp. (APH:TSX-V) (the “Company” or “ALDA”) announces that it has granted incentive stock options to certain directors, senior officers, employees and consultants to purchase an aggregate of 1,880,000 common shares at an exercise price of $0.10. 1,580,000 of the foregoing incentive stock options have a term of two years, expiring on August 2, 2008 and 300,000 of the foregoing incentive stock options granted to a consultant to the Company have a term of five years, expiring on August 2, 2011, but are subject to vesting on certain milestones. Options granted to consultants performing investor relations services to the Company will be subject to further vesting over the first twelve months after the grant in accordance with TSX Venture Exchange policy. The options and shares issuable upon exercise, if any, will be subject to a four-month hold period from the date of grant in accordance with TSX Venture Exchange policy. The grant was pursuant to the Company’s Rolling Stock Option Plan, which was re-affirmed by the shareholders of the Company on December 13, 2005 and subsequently accepted by the Exchange.
